This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
SYM2081 inhibits inflammation-driving mast cells in mouse models and human skin samples, paving the way for new topical treatments to prevent itching, hives, and other symptoms of skin conditions driven by mast cells, finds a study published in Science Translational Medicine. Im really excited about the clinical possibilities of this research, says senior author Daniel Kaplan, MD, PhD, Professor of Dermatology and Immunology at the University of Pittsburgh in Pittsburgh, PA, in a news release.
Discover 2024 skin cancer breakthroughs, including FDA approvals, innovative therapies, and updated clinical guidelines for melanoma and nonmelanoma care.
AnaptysBio, Inc.is pulling the plug on ANB032, an investigational B and T lymphocyte attenuator (BTLA )agonist that did not meet the primary and secondary endpoints in an atopic dermatitis (AD) study. The drug was being studied as a monotherapy for moderate-to-severe AD in the global, 201-patient ARISE-AD trial. Despite disappointing efficacy, ANB032 was well tolerated with no safety signals observed, the Company reported.
This term "collagen banking" has exploded in the past year, as a way to describe the process of amping up collagen production to ensure you have more of it later.
There was a lot wrong in the recent Huberman podcast featuring Shanna Swan - the misinformation was rapid fire. This episode features Lyle Burgoon PhD in a toxicologist reacts episode to break down some of the things that came up. From phthalates = endocrine disruptors? to feminization and the threat of human extinction?? There was a lot there, but we tried our best to cover their main points.
We took a peek at how spas across the country are offering self care to the clientele, and we selected these spas for their unique and effective approach to self care.
Allan experiences and shares his thoughts on OptiStrips. Silicone strips for comfortable glasses wear. Continue reading OptiStrips…adding comfort to wearing glasses at Spa Industry Association.
It’s been said that hairdressers are like therapists. For those of us who’ve tirelessly worked behind the chair doing hair while clients unload about their day, latest love or heartbreak, greatest achievement or recent failure, we know – to a very large degree – it’s true.
Veradermics closed a $75 million Series B financing which will be used to fund the ongoing pivotal clinical development of VDPHL01 for the treatment of androgenetic alopecia (AGA). VDPHL01 is a non-hormonal oral therapeutic. The first patient has been dosed in the pivotal Phase 2/3 trial evaluating VDPHL01 in AGA. The trial will enroll approximately 480 patients across 44 sites in the United States.
The U.S. Food and Drug Administration (FDA) has cleared Astria Therapeutics Investigational New Drug (IND) application to study STAR-0310 in atopic dermatitis (AD). STAR-0310 is a monoclonal antibody OX40 antagonist in preclinical development for the treatment of atopic dermatitis. A Phase 1a trial of STAR-0310 in healthy subjects is expected to initiate in the first quarter of 2025, with early proof-of-concept results expected in the third quarter of 2025.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
41 
Let's personalize your content